Nintedanib for lung scarring after bone marrow transplant
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests nintedanib to slow or improve bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a hematopoietic stem cell transplant. You may be considered if your breathing tests and scans show BOS, and if active infections and certain health risks are ruled out.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your transplant was 5 years or less ago
- You have BOS based on breathing test and scan rules, or a recent BOS diagnosis/change
- No current lung infection is found on recent tests (like chest X-ray/CT and cultures, if symptoms suggest)
- You can do breathing tests repeatedly (PFTs) and understand the study well enough to consent
- You are not pregnant or breastfeeding
- Your liver blood tests are not too high, unless explained by liver graft-versus-host disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody medicine called tezelumab for patients who develop a breathing problem called bronchiolitis obliterans syndrome (BOS) after a stem cell transplant. The trial aims to see if this medicine can reduce flare-ups and improve lung function.
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
This study tests whether the drug LAM-001 can help people who have developed a condition called bronchiolitis obliterans syndrome (BOS) after a double lung transplant. BOS causes a slow decline in lung function, and this trial aims to see if LAM-001 can slow or stop that decline.
This trial tests whether nintedanib, a drug that slows lung scarring, can help people with sarcoidosis-related lung fibrosis. It is for those who still have breathlessness or cough despite stable treatment.
This early trial tests if airway basal stem cells can help children with a serious lung condition called bronchiolitis obliterans. It aims to improve lung function and reduce the need for oxygen or breathing support.
This trial tests a drug called nintedanib to see if it can prevent radiation-related lung inflammation (pneumonia) in people with lung cancer that cannot be surgically removed. It may help protect your lungs during radiation treatment.
Hear when a new Bronchiolitis Obliterans Syndrome (BOS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.